Tim Illidge

20.5k total citations · 7 hit papers
218 papers, 11.0k citations indexed

About

Tim Illidge is a scholar working on Pathology and Forensic Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Tim Illidge has authored 218 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Pathology and Forensic Medicine, 121 papers in Oncology and 60 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Tim Illidge's work include Lymphoma Diagnosis and Treatment (126 papers), Monoclonal and Polyclonal Antibodies Research (35 papers) and CAR-T cell therapy research (35 papers). Tim Illidge is often cited by papers focused on Lymphoma Diagnosis and Treatment (126 papers), Monoclonal and Polyclonal Antibodies Research (35 papers) and CAR-T cell therapy research (35 papers). Tim Illidge collaborates with scholars based in United Kingdom, United States and France. Tim Illidge's co-authors include Jamie Honeychurch, Simon J. Dovedi, Mark S. Cragg, Eleanor J. Cheadle, Lena Specht, Robert W. Wilkinson, Jekaterina Ērenpreisa, Ian J. Stratford, Joachim Yahalom and Peter Hoskin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Tim Illidge

211 papers receiving 10.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

2014 974 citations Simon J. Dovedi, Amy L. Adlard et al. Cancer Research profile →
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

2012 711 citations Tim Illidge et al. Journal of Clinical Oncology profile →
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant

2015 463 citations Tim Illidge et al. profile →
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

2015 407 citations Tim Illidge, Peter Johnson et al. profile →
Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG)

2013 358 citations Lena Specht, Tim Illidge et al. International Journal of Radiation Oncology*Biology*Physics profile →
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2014 324 citations Tim Illidge et al. profile →
Immunomodulation by radiotherapy in tumour control and normal tissue toxicity

2021 167 citations Jamie Honeychurch, Tim Illidge et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Illidge United Kingdom	50	5.6k	4.8k	2.5k	2.4k	2.1k	218	11.0k
Jonathan W. Friedberg United States	61	6.5k 1.2×	9.1k 1.9×	1.9k 0.8×	1.3k 0.6×	1.2k 0.6×	393	12.7k
Franck Morschhauser France	56	6.7k 1.2×	8.8k 1.8×	2.3k 0.9×	1.1k 0.5×	2.1k 1.0×	447	12.3k
Stephen J. Schuster United States	48	8.3k 1.5×	4.7k 1.0×	2.9k 1.2×	928 0.4×	1.0k 0.5×	366	11.7k
Andres Forero‐Torres United States	39	5.1k 0.9×	3.5k 0.7×	1.6k 0.6×	1.1k 0.5×	1.3k 0.6×	162	7.6k
Nancy L. Bartlett United States	64	10.0k 1.8×	11.2k 2.4×	3.2k 1.3×	1.8k 0.8×	2.9k 1.3×	480	16.8k
Luis Fayad United States	50	5.5k 1.0×	6.3k 1.3×	1.7k 0.7×	782 0.3×	815 0.4×	334	9.7k
Barbara Pro United States	47	5.3k 1.0×	6.8k 1.4×	2.4k 0.9×	1.1k 0.5×	554 0.3×	289	9.9k
Paul J. Kurtin United States	64	3.6k 0.6×	5.1k 1.1×	2.2k 0.9×	1.1k 0.5×	687 0.3×	235	11.4k
Hans Tesch Germany	49	5.3k 0.9×	2.8k 0.6×	1.8k 0.7×	1.8k 0.8×	1.4k 0.7×	346	9.5k
Izidore S. Lossos United States	53	4.3k 0.8×	5.8k 1.2×	2.8k 1.1×	884 0.4×	680 0.3×	353	10.8k

Countries citing papers authored by Tim Illidge

Since Specialization

Citations

This map shows the geographic impact of Tim Illidge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Illidge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Illidge more than expected).

Fields of papers citing papers by Tim Illidge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Illidge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Illidge. The network helps show where Tim Illidge may publish in the future.

Co-authorship network of co-authors of Tim Illidge

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Illidge. A scholar is included among the top collaborators of Tim Illidge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Illidge. Tim Illidge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Dave, Sudhakar Sahoo, Peter Hoskin, et al.. (2023). Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer. International Journal of Molecular Sciences. 24(10). 8956–8956. 7 indexed citations

Price, James, Hitesh Mistry, Guy Betts, et al.. (2022). Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer. Journal of Clinical Oncology. 40(20). 2203–2212. 16 indexed citations

Hoskin, Peter, Caroline Brammer, Martin Robinson, et al.. (2021). 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. The Lancet Oncology. 22(3). 332–340. 62 indexed citations

Nakamura, Kyoko, Ankur Karmokar, Paul Farrington, et al.. (2021). Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control. Clinical Cancer Research. 27(15). 4353–4366. 43 indexed citations

Mukherjee, Debayan, et al.. (2021). The effect of hypoxia on PD-L1 expression in bladder cancer. BMC Cancer. 21(1). 1271–1271. 23 indexed citations

Mukherjee, Debayan, Rebecca E. Steele, Adam Pickard, et al.. (2020). Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. Cancers. 12(10). 2804–2804. 8 indexed citations

Dovedi, Simon J., Eleanor J. Cheadle, Edmund Poon, et al.. (2017). Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. Clinical Cancer Research. 23(18). 5514–5526. 263 indexed citations

Dovedi, Simon J., Grazyna Lipowska‐Bhalla, Stephen A. Beers, et al.. (2016). Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells. Cancer Immunology Research. 4(7). 621–630. 44 indexed citations

Bröckelmann, Paul J., Erin Zagadailov, Shelby Corman, et al.. (2016). Brentuximab vedotin in patients who are ineligible for autologous stem cell transplant with relapsed or refractory Hodgkin lymphoma: a United Kingdom and Germany retrospective study.. Haematologica. 1 indexed citations

10.

Maraldo, Maja V., Bouthaina S. Dabaja, Andrea Riccardo Filippi, et al.. (2015). Radiation Therapy Planning for Early-Stage Hodgkin Lymphoma: Experience of the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology*Biology*Physics. 92(1). 144–152. 17 indexed citations

11.

Dovedi, Simon J., Amy L. Adlard, Grazyna Lipowska‐Bhalla, et al.. (2014). Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Research. 74(19). 5458–5468. 974 indexed citations breakdown →

12.

Oscier, David, Claire Dearden, Efrem Eren, et al.. (2012). Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. British Journal of Haematology. 159(5). 541–564. 114 indexed citations

13.

Lowry, Lisa, Paul Smith, Wendi Qian, et al.. (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial. Radiotherapy and Oncology. 100(1). 86–92. 247 indexed citations

14.

Alduaij, Waleed, Andrei Ivanov, Jamie Honeychurch, et al.. (2011). Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 117(17). 4519–4529. 222 indexed citations

15.

Ferrer, Ludovic, Caroline Bodet‐Milin, Steven Le Gouill, et al.. (2010). Comparison of dosimetric approaches for Non-Hodgkin lymphoma in radioimmunotherapy. European Journal of Nuclear Medicine and Molecular Imaging. 1 indexed citations

16.

Illidge, Tim. (2009). Radioimmunotherapy in non-Hodgkin’s lymphoma: can it change the course of the disease?. 1(5).

17.

Du, Yong, Jamie Honeychurch, Martin J. Glennie, Peter Johnson, & Tim Illidge. (2007). Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma. Cancer Research. 67(3). 1335–1343. 8 indexed citations

18.

Ellison, David W., et al.. (2001). Anti-Yo Antibody-Positive Cerebellar Degeneration Associated with Endometrial Carcinoma: Case Report and Review of the Literature. Clinical Oncology. 13(6). 476–479. 17 indexed citations

19.

Illidge, Tim, et al.. (2001). Antibodies in the Treatment of Lymphoma. Clinical Oncology. 13(4). 251–261. 2 indexed citations

20.

Illidge, Tim, et al.. (2000). A New in Vivo and in Vitro B cell Lymphoma Model, π-BCL1. Cancer Biotherapy and Radiopharmaceuticals. 15(6). 571–580. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact